20 Oct 2026
18:00 CEST |
ABL Diagnostics |
ABL Texcell Diagnostics Announces Termination of Vela Diagnostics Letter of Intent
|
20103010 Biotechnology |
Mergers, Acquisitions, Transfers |
20 Oct 2026
18:00 CEST |
ABL Diagnostics |
ABL TEXCELL DIAGNOSTICS ANNONCE LA RÉSILIATION DE LA LETTRE D’INTENTION RELATIVE À VELA DIAGNOSTICS
|
20103010 Biotechnology |
Mergers, Acquisitions, Transfers |
19 Oct 2026
18:00 CEST |
ABL Diagnostics |
ABL Texcell Diagnostics Strengthens the Foundations of a Stable Shareholder Base and Pursues Its Growth Strategy
|
20103010 Biotechnology |
Other subject |
19 Oct 2026
18:00 CEST |
ABL Diagnostics |
ABL TEXCELL DIAGNOSTICS RENFORCE LES CONDITIONS D’UN ACTIONNARIAT STABLE ET POURSUIT SA STRATÉGIE DE CROISSANCE
|
20103010 Biotechnology |
Other subject |
16 Oct 2026
17:15 CEST |
ABL Diagnostics |
ABL TEXCELL DIAGNOSTICS : DÉCLARATION D’APPEL DU MINISTÈRE PUBLIC RELATIVE AU JUGEMENT DE CESSION D’INTEGRAGEN
|
20103010 Biotechnology |
Mergers, Acquisitions, Transfers |
16 Oct 2026
17:15 CEST |
ABL Diagnostics |
ABL Texcell Diagnostics: Notice of Appeal by the Public Prosecutor Regarding the IntegraGen Transfer Judgment
|
20103010 Biotechnology |
Mergers, Acquisitions, Transfers |
12 Oct 2026
08:00 CEST |
ABL Diagnostics |
ABL Texcell Diagnostics Strengthens Its Presence at Genopole and Opens a New Chapter in Precision Oncology With the Acquisition of IntegraGen’s Assets and Operations
|
20103010 Biotechnology |
Mergers, Acquisitions, Transfers |
12 Oct 2026
08:00 CEST |
ABL Diagnostics |
ABL TEXCELL DIAGNOSTICS RENFORCE SON ANCRAGE AU GENOPOLE ET OUVRE UN NOUVEAU CHAPITRE DE DÉVELOPPEMENT EN ONCOLOGIE DE PRÉCISION AVEC LA REPRISE DES ACTIFS ET DES ACTIVITÉS D’INTEGRAGEN
|
20103010 Biotechnology |
Mergers, Acquisitions, Transfers |
08 Oct 2026
13:00 CEST |
ABL Diagnostics |
ABL Texcell Diagnostics Announces Availability of All Invest Securities Research Flash Note #8
|
20103010 Biotechnology |
Trends / Analyses |
08 Oct 2026
13:00 CEST |
ABL Diagnostics |
ABL TEXCELL DIAGNOSTICS ANNONCE LA PUBLICATION DE LA NOTE FLASH N° 8 ALL INVEST SECURITIES RESEARCH
|
20103010 Biotechnology |
Trends / Analyses |
01 Oct 2026
18:00 CEST |
ABL Diagnostics |
ABL TEXCELL DIAGNOSTICS RELÈVE SON OBJECTIF DE CHIFFRE D’AFFAIRES 2026 À UNE FOURCHETTE DE 13,5 M€ À 14,0 M€
|
20103010 Biotechnology |
Sales |
01 Oct 2026
18:00 CEST |
ABL Diagnostics |
ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million
|
20103010 Biotechnology |
Sales |
30 Sep 2026
23:30 CEST |
ABL Diagnostics |
ABL TEXCELL DIAGNOSTICS : MISE À DISPOSITION DU RAPPORT SEMESTRIEL 2026
|
20103010 Biotechnology |
Legal |
30 Sep 2026
23:30 CEST |
ABL Diagnostics |
ABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial Report
|
20103010 Biotechnology |
Legal |
21 Sep 2026
19:00 CEST |
ABL Diagnostics |
ABL Texcell Diagnostics franchit une nouvelle étape stratégique avec un projet d’acquisition des activités de Vela Diagnostics à Singapour et aux États-Unis
|
20103010 Biotechnology |
Alliances and agreements |
21 Sep 2026
19:00 CEST |
ABL Diagnostics |
ABL Texcell Diagnostics Reaches a New Strategic Milestone With a Proposed Acquisition of Vela Diagnostics' Activities in Singapore and the United States
|
20103010 Biotechnology |
Alliances and agreements |
18 Sep 2026
20:00 CEST |
ABL Diagnostics |
ABL TEXCELL DIAGNOSTICS :MODIFICATION DES RESSOURCES ALLOUEES AU CONTRAT DE LIQUIDITE
|
20103010 Biotechnology |
Legal |
17 Sep 2026
20:00 CEST |
ABL Diagnostics |
ABL Diagnostics Becomes ABL Texcell Diagnostics
|
20103010 Biotechnology |
Legal |
17 Sep 2026
20:00 CEST |
ABL Diagnostics |
ABL DIAGNOSTICS DEVIENT ABL TEXCELL DIAGNOSTICS
|
20103010 Biotechnology |
Legal |
17 Sep 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics Announces Its Participation in Investor Access @ Maison De La Chimie Paris 2026
|
20103010 Biotechnology |
Other subject |
17 Sep 2026
18:00 CEST |
ABL Diagnostics |
ABL DIAGNOSTICS ANNONCE SA PARTICIPATION À INVESTOR ACCESS @ MAISON DE LA CHIMIE PARIS 2026
|
20103010 Biotechnology |
Other subject |
15 Sep 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics to Participate in the European Main MidCap Event Paris 2026 on September 30 and October 1, 2026
|
20103010 Biotechnology |
Other subject |
15 Sep 2026
18:00 CEST |
ABL Diagnostics |
ABL DIAGNOSTICS PARTICIPERA AU EUROPEAN MAIN MIDCAP EVENT PARIS 2026 LES 30 SEPTEMBRE ET 1er OCTOBRE 2026
|
20103010 Biotechnology |
Other subject |
14 Sep 2026
20:00 CEST |
ABL Diagnostics |
ABL Diagnostics Announces Availability of the Latest All Invest Securities Research Report
|
20103010 Biotechnology |
Rating |
14 Sep 2026
20:00 CEST |
ABL Diagnostics |
ABL Diagnostics annonce la mise à disposition du dernier rapport d'analyse d'All Invest Securities
|
20103010 Biotechnology |
Rating |
11 Sep 2026
12:01 CEST |
ABL Diagnostics |
ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen
|
20103010 Biotechnology |
Mergers, Acquisitions, Transfers |
11 Sep 2026
12:01 CEST |
ABL Diagnostics |
ABL Diagnostics (ABLD) annonce le dépôt d’une offre de reprise de IntegraGen
|
20103010 Biotechnology |
Mergers, Acquisitions, Transfers |
10 Sep 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics - TEXCELL Strengthens Its Position as an International Reference in Safety and Viral Clearance With a New Strategic Partnership With ABIONYX Pharma
|
20103010 Biotechnology |
Alliances and agreements |
10 Sep 2026
18:00 CEST |
ABL Diagnostics |
ABL DIAGNOSTICS - TEXCELL RENFORCE SA POSITION DE RÉFÉRENCE INTERNATIONALE EN SÉCURITÉ ET CLAIRANCE VIRALE AVEC UN NOUVEAU PARTENARIAT STRATÉGIQUE AVEC ABIONYX PHARMA
|
20103010 Biotechnology |
Alliances and agreements |
08 Sep 2026
18:28 CEST |
ABL Diagnostics |
ABL DIAGNOSTICS CONFIRME SON CHANGEMENT D’ÉCHELLE AU PREMIER SEMESTRE 2026 : CHIFFRE D’AFFAIRES EN CROISSANCE DE 90,0 %, EBITDA MULTIPLIÉ PAR PLUS DE QUATRE ET RÉSULTAT NET EN HAUSSE DE 343,3 % PAR RAPPORT AU PREMIER SEMESTRE 2025
|
20103010 Biotechnology |
Income |
08 Sep 2026
18:28 CEST |
ABL Diagnostics |
ABL Diagnostics Confirms Its Change of Scale in the First Half of 2026: Revenue up 90.0%, EBITDA Multiplied by More Than Four and Net Income up 343.3% Compared to the First Half of 2025
|
20103010 Biotechnology |
Income |
27 Aug 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics: Information Relating to the Total Number of Voting Rights and the Number of Shares Constituting the Share Capital
|
20103010 Biotechnology |
General meeting / Board Meeting |
27 Aug 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
|
20103010 Biotechnology |
General meeting / Board Meeting |
27 Aug 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics: Ordinary and Extraordinary General Meeting of September 17, 2026 – Arrangements for the Availability and Consultation of Preparatory Documents
|
20103010 Biotechnology |
General meeting / Board Meeting |
27 Aug 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics : ASSEMBLÉE GÉNÉRALE ORDINAIRE ET EXTRAORDINAIRE DU 17 SEPTEMBRE 2026 – MODALITÉS DE MISE À DISPOSITION OU DE CONSULTATION DES DOCUMENTS PRÉPARATOIRES
|
20103010 Biotechnology |
General meeting / Board Meeting |
07 Aug 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics - Projet de transfert de la cotation de ses titres du marché réglementé d'Euronext Paris vers Euronext Growth Paris
|
20103010 Biotechnology |
General meeting / Board Meeting |
07 Aug 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris
|
20103010 Biotechnology |
General meeting / Board Meeting |
29 Jul 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL
|
20103010 Biotechnology |
Other subject |
29 Jul 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics : Cession d'un nouveau bloc d'actions par son actionnaire principal ABL
|
20103010 Biotechnology |
Other subject |
27 Jul 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital
|
20103010 Biotechnology |
Other subject |
27 Jul 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics annonce la signature d'un avenant au contrat d'Equity Line et de prêt de titres entre son actionnaire principal ABL SA (Luxembourg) et Alumni Capital
|
20103010 Biotechnology |
Other subject |
23 Jul 2026
09:22 CEST |
ABL Diagnostics |
ABL Diagnostics désignée par le Tribunal de commerce d'Évry pour la reprise des activités de TEXCELL
|
20103010 Biotechnology |
Other financial transaction |
23 Jul 2026
09:22 CEST |
ABL Diagnostics |
ABL Diagnostics Selected by the Évry Commercial Court to Acquire TEXCELL’s Operations
|
20103010 Biotechnology |
Other financial transaction |
22 Jul 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL
|
20103010 Biotechnology |
Other financial transaction |
22 Jul 2026
18:00 CEST |
ABL Diagnostics |
ABL Diagnostics : Cession d'un nouveau bloc d'actions par son actionnaire principal ABL
|
20103010 Biotechnology |
Other financial transaction |
15 Jul 2026
08:00 CEST |
ABL Diagnostics |
ABL Diagnostics Informed that its Reference Shareholder ABL Has Crossed Below the 95% Threshold
|
20103010 Biotechnology |
Legal |
15 Jul 2026
08:00 CEST |
ABL Diagnostics |
ABL Diagnostics informée du franchissement à la baisse du seuil de 95 % par son actionnaire de référence ABL
|
20103010 Biotechnology |
Legal |
13 Jul 2026
08:00 CEST |
ABL Diagnostics |
ABL DIAGNOSTICS : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ S1 2026
|
20103010 Biotechnology |
Legal |
10 Jul 2026
08:00 CEST |
ABL Diagnostics |
ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL
|
20103010 Biotechnology |
Share history |
10 Jul 2026
08:00 CEST |
ABL Diagnostics |
ABL Diagnostics : Cession d'un nouveau bloc d'actions par son actionnaire principal ABL
|
20103010 Biotechnology |
Share history |